Canaccord analyst Whitney Ijem lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $68 from $74 and keeps a Buy rating on the shares. The firm said its 4Q24 earnings report had positive pipeline updates with key programs on track and are removing net profits from COVID revenue from 2025 estimates, in line with the expected gross profit from sales of Kostaive offsetting the company’s share of development costs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- 3 Best Stocks to Buy Now, 3/10/2025, According to Top Analysts
- Arcturus Therapeutics’ Earnings Call: Mixed Outlook with Strategic Wins
- Arcturus Therapeutics price target lowered to $60 from $63 at H.C. Wainwright
- Positive Outlook for Arcturus Therapeutics: Strong Vaccine Sales and Promising Cystic Fibrosis Program Drive Buy Rating
- Arcturus Therapeutics Reports 2024 Financial Results and Pipeline Progress